-G Vassal Researcher Activity Profile

Research Author Detailed Information 

G Vassal Publication Rate By Year

G Vassal has published 1 paper(s) in 2005, 18 paper(s) in 2007, 3 paper(s) in 2008, for a total of 22 research publications in total.

G G Vassal Author Information

LAST NAME: vassal

FIRST NAME: G

INITIALS: g

AFFILIATION:

Papers

G Vassal's Publication Record

1. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Year Published: 2007
Institut Regional du Cancer Nantes Atlantique, Dept de Recherche Therapeutique, CLCC Rene Gauducheau, Nantes, France.
2. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Year Published: 2007
Institut Gustave Roussy, Villejuif, France.
3. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Year Published: 2007
Institut Gustave Roussy, Villejuif, France.
4. [Translational research and Cancer Plan.] Year Published: 2007
5. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Year Published: 2007
Institut Regional du Cancer Nantes Atlantique, Dept de Recherche Therapeutique, CLCC Rene Gauducheau, Nantes, France.
6. [Translational research and Cancer Plan] Year Published: 2007
7. [Translational research and Cancer Plan] Year Published: 2007
8. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Year Published: 2008
Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.
9. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. Year Published: 2007
UPRES EA3535 Pharmacology and New Cancer Treatments, Institute Gustave Roussy - IFR54 and Paris XI University, 94800 Villejuif, France.
10. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Year Published: 2007
11. The Chemokine Receptor CXCR4 Strongly Promotes Neuroblastoma Primary Tumour and Metastatic Growth, but not Invasion. Year Published: 2007
Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland.
12. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. Year Published: 2007
UPRES EA3535 Pharmacology and New Cancer Treatments, Institute Gustave Roussy - IFR54 and Paris XI University, 94800 Villejuif, France.
13. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Year Published: 2007
14. The Chemokine Receptor CXCR4 Strongly Promotes Neuroblastoma Primary Tumour and Metastatic Growth, but not Invasion. Year Published: 2007
Department of Paediatrics, Paediatric Oncology Research, University Hospital Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland.
15. Do medulloblastoma tumors meet the food and drug administration criteria for anti-erbB2 therapy with trastuzumab? Year Published: 2007
16. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. Year Published: 2007
UPRES EA3535 Pharmacology and New Cancer Treatments, Institute Gustave Roussy - IFR54 and Paris XI University, 94800 Villejuif, France.
17. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Year Published: 2005
Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, 94805 Villejuif, France. le_deley@igr.fr
18. Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab? Year Published: 2007
19. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Year Published: 2007
20. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Year Published: 2007
CNRS & Université Paris XI, Pharmacotechnie, BiopharmacieChatenay Malabry, France.
21. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Year Published: 2008
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, 79106 Freiburg, Germany. jochen.roessler@uniklinik-freiburg.de
22. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Year Published: 2008
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, 79106 Freiburg, Germany. jochen.roessler@uniklinik-freiburg.de.